Cite
Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.
MLA
Sailer, Verena, et al. “Clinical Performance Validation of PITX2 DNA Methylation as Prognostic Biomarker in Patients with Head and Neck Squamous Cell Carcinoma.” PLoS ONE, vol. 12, no. 6, June 2017, pp. 1–12. EBSCOhost, https://doi.org/10.1371/journal.pone.0179412.
APA
Sailer, V., Gevensleben, H., Dietrich, J., Goltz, D., Kristiansen, G., Bootz, F., & Dietrich, D. (2017). Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma. PLoS ONE, 12(6), 1–12. https://doi.org/10.1371/journal.pone.0179412
Chicago
Sailer, Verena, Heidrun Gevensleben, Joern Dietrich, Diane Goltz, Glen Kristiansen, Friedrich Bootz, and Dimo Dietrich. 2017. “Clinical Performance Validation of PITX2 DNA Methylation as Prognostic Biomarker in Patients with Head and Neck Squamous Cell Carcinoma.” PLoS ONE 12 (6): 1–12. doi:10.1371/journal.pone.0179412.